Table 4.
The interaction of BDNF Val/Met polymorphism and FRAP on anthropometric indices, lipid profile and atherogenic indices.
| Variable | Allele | High adherence of FRAP | |||
|---|---|---|---|---|---|
| β | 95% CI | P | |||
| BMI | Crud | Met/Met | 0.55 | − 1.94 to 3.04 | 0.66 |
| Val/Met | 0.66 | − 0.88 to 2.21 | 0.40 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | 0.64 | − 1.85 to3.12 | 0.61 | |
| Val/Met | 0.72 | − 0.81 to 2.26 | 0.35 | ||
| Val/Val | Reference | ||||
| WC | Crud | Met/Met | − 0.15 | − 5.92 to 5.60 | 0.86 |
| Val/Met | 0.48 | − 3.11 to 4.07 | 0.79 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | − 0.48 | − 6.09 to 5.11 | 0.86 | |
| Val/Met | 0.23 | − 3.25 to 3.73 | 0.89 | ||
| Val/Val | Reference | ||||
| HDL | Crud | Met/Met | − 7.25 | − 14.04 to − 0.47 | 0.03 |
| Val/Met | − 4.39 | − 8.63 to − 0.16 | 0.04 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | − 6.10 | − 12.69 to 0.49 | 0.07 | |
| Val/Met | − 4.18 | − 8.29 to − 0.68 | 0.04 | ||
| Val/Val | Reference | ||||
| TG | Crud | Met/Met | 25.52 | − 32.43 to 83.48 | 0.86 |
| Val/Met | 49.98 | 13.86 to 86.11 | 0.007 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | 24.16 | − 34.37 to 82.71 | 0.41 | |
| Val/Met | 51.84 | 15.39 to 88.30 | 0.005 | ||
| Val/Val | Reference | ||||
| LDL | Crud | Met/Met | − 1.66 | − 20.67 to 17.33 | 0.43 |
| Val/Met | − 0.43 | − 12.30 to 11.43 | 0.07 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | 3.37 | − 15.55 to 22.31 | 0.72 | |
| Val/Met | 0.16 | − 11.64 to 11.97 | 0.97 | ||
| Val/Val | Reference | ||||
| TC | Crud | Met/Met | − 25.42 | − 62.49 to 11.64 | 0.17 |
| Val/Met | 19.56 | − 3.64 to 42.77 | 0.09 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | − 22.09 | − 59.24 to 15.06 | 0.24 | |
| Val/Met | 21.79 | − 1.44 to 45.03 | 0.06 | ||
| Val/Val | Reference | ||||
| AIP | Crud | Met/Met | 0.07 | − 0.05 to 0.20 | 0.23 |
| Val/Met | 0.12 | 0.03 to 0.20 | 0.004 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | 0.06 | − 0.06 to 0.20 | 0.30 | |
| Val/Met | 0.12 | 0.04 to 0.20 | 0.003 | ||
| Val/Val | Reference | ||||
| AC | Crud | Met/Met | − 0.02 | − 0.84 to 0.78 | 0.94 |
| Val/Met | 0.57 | 0.05 to 1.08 | 0.02 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | − 0.06 | − 0.87 to 0.75 | 0.87 | |
| Val/Met | 0.59 | 0.08 to 1.10 | 0.02 | ||
| Val/Val | Reference | ||||
| LDL/HDL.CRI.II | Crud | Met/Met | 0.23 | − 0.12 to 0.59 | 0.21 |
| Val/Met | 0.05 | − 0.16 to 0.28 | 0.62 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | 0.27 | − 0.08 to 0.62 | 0.13 | |
| Val/Met | 0.05 | − 0.16 to 0.27 | 0.60 | ||
| Val/Val | Reference | ||||
| TC/HDL.CRI.I | Crud | Met/Met | − 0.25 | − 1.10 to 0.59 | 0.55 |
| Val/Met | 0.20 | − 0.72 to 0.31 | 0.43 | ||
| Val/Val | Reference | ||||
| Adjusted | Met/Met | − 0.28 | − 1.13 to 0.56 | 0.51 | |
| Val/Met | − 0.18 | − 0.74 to 0.34 | 0.49 | ||
| Val/Val | Reference | ||||
Val/Val genotype is considered as a reference. Low adherence of DTAC is considered as a reference. Generalized linear model; crude model and adjusted model Age, physical activity, sex, smoking, alcohol, energy intake, lipid, and glucose-lowering medicines, and family history of diabetes, as covariates. Bold values denote statistical signifcance at the P < 0.05 level.
FRAP ferric reducing ability of plasma, CI confidence interval, AIP (Atherogenic index of plasma): log(TG/HDL), AC (Atherogenic coefficient): (TC-HDL/HDL), CRI-II (Castelli s risk index): LDL/HDL, CRI-I (Castelli s risk index): TC/HDL, TC total cholesterol, TG triglyceride, HDL high density lipoprotein, LDL low density lipoprotein, WC waist circumference.